Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion.
This study suggests that ketamine is effective in treatment-resistant bipolar depression and may reduce suicidal ideation and anhedonia.
At least 10-20% of the patients suffering from depression meet criteria for treatment-resistant depression (TRD)...
Our meta-analysis suggests that single administrations ketamine therapy are efficacious in the rapid treatment of unipolar and bipolar depression.
Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment.